Table 3.
Safety outcome random-effects meta-analysis summary table.
| Toxicity | No. of studies | Total patients | Median follow-up range (Median) (months) | No. (%) of T3/T4 disease patients | Heterogeneity test | Proportion (95 % confidence interval) |
|---|---|---|---|---|---|---|
| I2 | ||||||
| Primary NPC patients | ||||||
| Grade ≥ 3 dermatitis | 9 | 346 | 14–69 (25) | N/A a | 81 % | 12 % (5 %-26 %) |
| Grade 2 mucositis | 9 | 326 | 14–69 (25) | N/A a | 50 % | 42 % (34 %-50 %) |
| Grade ≥ 3 mucositis | 10 | 406 | 14–69 (25) | N/A a | 71 % | 11 % (6 %-19 %) |
| Grade 2 xerostomia | 9 | 308 | 19–69 (32) | N/A a | 72 % | 22 % (13 %-36 %) |
| Grade ≥ 3 xerostomia | 8 | 281 | 19–69 (32) | N/A a | 0 % | 2 % (1 %-4%) |
| Grade ≥ 3 late toxicity | 5 | 167 | 22–90 (32) | N/A a | 70 % | 15 % (5 %-35 %) |
| Nasogastric/Gastrostomy tube required | 10 | 331 | 14–69 (25) | N/A a | 84 % | 13 % (5 %-31 %) |
Note: aUnable to extract data from some studies.